Safety and efficacy of memantine extended-release in the management of alzheimer's disease

Clinical Medicine Insights: Therapeutics

Volumn 5, Issue , 2013, Pages 95-102

  Corbett, Anne ^a   Francis, Paul ^a   Ballard, Clive ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's; BPSD; Efficacy; Memantine; Safety; Treatment

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; BALANCE DISORDER; BEHAVIORAL AND PSYCHOLOGICAL SYMPTOM IN DEMENTIA; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONFUSION; CONSTIPATION; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOWN SYNDROME; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; GAIT DISORDER; HALLUCINATION; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; MULTIINFARCT DEMENTIA; MYCOSIS; NONHUMAN; OUTCOME ASSESSMENT; PANCREATITIS; PARKINSON DISEASE; PSYCHOSIS; REVIEW; SEIZURE; SOMNOLENCE; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 84877601800     PISSN: 1179559X     EISSN: None     Source Type: Journal    
DOI: 10.4137/CMT.S7794     Document Type: Review

References (58)

1. Alzheimer's Disease International World Alzheimer Report: http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf. 2009. Accessed Mar 2013.
2. Wimo A, Jonsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9(1):1-11. e13.
3. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009;2:CD001191.
4. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:CD001190.
5. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;1:CD001747.
6. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14): 1333-41.
7. van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):136-43.
8. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135-46.
9. National Institute of Clinical Excellence: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's Disease http://guidance.nice.org.uk/TA111. Technology Appraisals 2011. Accessed Mar 2013.
10. Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease-a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res. 2000;2(2-3):85-97.
11. Francis PT, Parsons CG, Jones RW. Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. Expert Rev Neurother. 2012;12(11):1351-65.
12. Procter AW, Francis PT, Holmes C, et al. Beta-Amyloid precursor protein isoforms show correlations with neurones but not with glia of demented subjects. Acta Neuropathol. 1994;88(6):545-52.
13. Kirvell SL, Esiri M, Francis PT. Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J Neurochem. 2006;98(3):939-50.
14. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res. 2002;958(1):210-21.
15. Willard LB, Hauss-Wegrzyniak B, Danysz W, Wenk GL. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp Brain Res. 2000;134(1):58-65.
16. Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol. 1995;293(3):267-70.
17. Wenk GL, Danysz W, Roice DD. The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. Neuroreport. 1996;7(9):1453-6.
18. Francis PT. Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. Current Mol Pharmacol. 2009; 2(1):77-82.
19. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969-77.
20. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613-8.
21. Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord. 2009;24(8):1217-21.
22. Wilcock G, Mobius HJ, Stoffler A; MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17(6):297-305.
23. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834-9.
24. Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699-723.
25. Koch HJ, Szecsey A, Haen E. NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia. Curr Pharm Des. 2004;10(3):253-9.
26. European Medicines Agency: Memantine hydrochloride-Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000463/WC500058763.pdf. 2012. Accessed Mar 2013.
27. Jones RW, Bayer A, Inglis F, Barker A, Phul R. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry. 2007; 22(3):258-62.
28. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;2:CD003154.
29. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291(3):317-24.
30. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366(10): 893-903.
31. McShane R, Areora Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2009.
32. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open. 2012;2(3). 33.
33. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-50_final.pdf. Accessed Mar 8, 2013.
34. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83-9.
35. Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):6.
36. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Dis. 2008;22(3):209-21.
37. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170-7.
38. Paleacu D, Barak Y, Mirecky I, Mazeh D. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry. 2008;23(4):393-400.
39. Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf. 2011;10(1):35-43.
40. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525-38.
41. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. Mar 2006;14(3):191-210.
42. Suh GH, Son HG, Ju YS, et al. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry. Sep-Oct 2004;12(5):509-16.
43. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134-43.
44. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60(2):107-15.
45. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007;22(5):475-84.
46. Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry. 2001;16(12):1156-62.
47. Corbett A, Ballard C. Antipsychotics and mortality in dementia. Am J Psychiatry. 2012;169(1):7-9.
48. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-7.
49. Ballard CG, Margallo-Lana M, Fossey J, et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry. Aug 2001;62(8):631-6.
50. Gauthier S, Herrmann N, Ferreri F, Agbokou C. Use of memantine to treat Alzheimer's disease. CMAJ. 2006;175(5):501-2.
51. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20(5):459-64.
52. Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67(1):57-63.
53. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341-8.
54. Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PloS One. 2012;7(5):e35185.
55. Ballard CG. A Randomized Controlled trial comparing memantine and antipsychotics for the prophylaxis of Agitation in people with Alzheimer's disease Alzheimer's Association International Conference. Vancouver; Jul 14th-19th, 2012.
56. Behar TN, Colton CA. Redox regulation of neuronal migration in a Down Syndrome model. Free radical biology and medicine. 2003;35(6):566-75.
57. Begni B, Brighina L, Fumagalli L, et al. Altered glutamate uptake in peripheral tissues from Down syndrome patients. Neurosci Lett. 2003; 343(2):73-6.
58. Hanney M, Prasher V, Williams N, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9815):528-36.